Biomet was a large manufacturer of hip replacement products before it was bought by its competitor Zimmer. Several Biomet hip implants helped improve patient’s lives, but one line of products didn’t live up to expectations. Biomet’s metal-on-metal implants cost the company millions of dollars in litigation and compensation costs.
Indiana-based Biomet Orthopedics was a medical device manufacturer that specialized in surgical products to replace the hip, knee, shoulder and other joints. Orthopedic manufacturer Zimmer bought Biomet in 2014 for $13.4 billion. The new company, Zimmer Biomet, became one of the leaders in the hip replacement market in 2016.
Before the acquisition, Biomet’s top hip replacement product was the Acros Modular Femoral Revision System. It included five stems and three body options that could be implanted using three different types of surgical techniques.
The company also sold acetabular components, including products in its G7 Acetabular System and Regenerex RingLoc+ Modular Acetabular System. The company’s products had well-documented histories of success, but Biomet was not immune to failures.
The M2a Magnum hip implant products contained problematic metal-on-metal designs. The M2a Magnum caused a variety of complications, including metallosis, which is metal poisoning that occurs when metal particles are released into the blood from the artificial joint.
The U.S. Food and Drug Administration received hundreds of reports of complications from doctors and patients who used the M2a Hip implant line of products. However, the devices were never recalled. Thousands of people filed lawsuits against the manufacturer, and Biomet agreed to settle a large number of cases in 2014. However, 466 lawsuits were still pending against the company in August 2017.
Injured by a Biomet hip implant? We can help.Get a Free Case Review
Biomet manufactured hip replacement devices for all types of hip replacement surgeries. These devices included femoral, acetabular and revision components. Revision components are used in surgery to replace faulty or failed implants from original hip replacement surgery.
Biomet’s implants came in a variety of materials such as ceramic, metal and polyethylene plastic. The company claimed that components manufactured with its exclusive E1 Antioxidant Infused Technology had a lower wear rate than other polyethylene products.
Biomet Products, Hip Systems and Components
Primary Femoral Components
|Answer Hip System||Balance Femoral Component|
|Bi-Metric Porous Primary Femoral Component||Bi-Metric Interlok Femoral Component|
|Bio-Groove HA Hip System||Biomet Hip Fracture Femoral Component|
|Bio-Moore II Hip System||Generation 4 Polished Hips System|
|Integral Centralizer Femoral Component||Integral Reduced Proximal Profile Femoral Component|
|Rx 90 Smooth Primary Femoral Component||Stanmore Hip System|
|Mallory-Head Interlok Femoral Component||Taperloc Hip System|
Revision Femoral Components
|Bi-Metric Head/Neck Replacements||Reach Revision System|
|Bi-Metric Long Stems||Rx 90 Revision System|
|Integral 180 Femoral Component||Mallory-Head 1pc Calcar Femoral Component|
|PLR Proximal Loading Revision Stem||Mallory-Head Modular Calcar Revision System|
|Reach Modular Revision System||Arcos Modular Femoral Revision System|
Primary Acetabular Components
|Bio-Clad Polyethylene Acetabular Component||C2a – Taper Acetabular System|
|Full Hemisphere Solid Acetabular Component||M2a – Ringloc Liner|
|M2a – Taper Acetabular Hip System||M2a – 38 Metal-on-Metal Acetabular Hip System|
|QSAC Quadrant Sparing Acetabular Component||Ranawat/Burstein Polyethylene Acetabular Component|
|RingLoc Acetabular Liners||RingLoc Acetabular Series|
|RingLoc Bi-Polar Articulating Hip System||Rx 90 Low Profile Acetabular Component|
|Rx 90 Polyethylene Acetabular Component||Tri-Spike Acetabular Component|
|Universal Acetabular Component||Vision Acetabular Component|
|Mallory-Head Radial Acetabular Shell||M2a-Magnum Large Metal Articulation|
Revision Acetabular Components
|Biomet Tri-Polar Acetabular System|
|Freedom Constrained Liner|
|Healey Flanged Revision Acetabular Component|
|Par 5 Acetabular Reconstruction System|
|Recovery Protrusio Cage|
|Mallory-Head +5 Acetabular Component|
|Regenerex Acetabular Reconstruction System|
In addition to its popular M2a Magnum line of implants, Biomet manufactured other metal-on-metal designs, including the Biomet Stanmore and Exceed ABT. According to Biomet, the company produced the widest range of metal-on-metal hip devices in the industry.
The company released its lucrative M2a line of implant products in 1996, beginning with the M2a RingLoc. From 1999 to 2009, more than 110,000 M2a devices were implanted in patients. Biomet claimed the M2a design increased long-term performance, allowed for a wider range of motion and decreased dislocation rates.
The M2a line included the following models:
The M2a Magnum Large Metal Articulation device was released in the Unites States in 2004 and was one of the company’s bestselling devices. Following the release of this device, all M2a implants were consolidated under the M2a Magnum brand.
The devices were monoblock implants, meaning they were composed of a single component, and each M2a model had slight differences in design to accommodate different patient needs. The M2a Magnum line included several acetabular products composed of a cup (or shell), metal liner and metal ball.
The M2a Magnum Large Metal Articulation System was endorsed by former Olympian Mary Lou Retton, who suffered from hip dysplasia and damage to her hips during her career as a gymnast. Retton received a total hip replacement using this device, along with Biomet’s Taperloc Hip Stem, in 2005.
M2a implants were designed for active people. The larger head diameter had the potential for more than 160 degrees of motion. The downside to the larger heads was that the surface area rubbing against the inside of the cup was larger, which increased surface wear. That meant more metal particles could be released into the blood and surrounding tissues.
More than 450 adverse events involving Magnum implants were reported to the FDA by patients and doctors. Complications included pain, swelling, premature device failure and fractures that required revision surgery.
A number of people developed pain and disability as a result of the M2a Magnum. Thousands filed lawsuits against Biomet over the design.
In October 2012, a federal judicial panel centralized Biomet M2a Magnum hip implant lawsuits in the Northern District of Indiana. Judge Robert L. Miller Jr. presided over the litigation known as Multidistrict Litigation No. 2391.
Multidistrict litigation is used to consolidate similar cases and improve court efficiency. More than 2,663 people filed lawsuits in the MDL.
Patricia Gill, from New York, received an M2a Magnum implant in 2005 in her right hip. In a lawsuit, she claimed that friction and wear between the metal components released chromium particles into her blood and tissues, causing severe pain and inflammation. She received revision surgery to replace the implant. She sought compensation for medical expenses, pain and suffering, lost wages and punitive damages.
Christina Kirk, an Ohio woman, received an M2a Magnum hip implant when she underwent a total right hip replacement in 2007. She claimed that she suffered severe physical injuries caused by the release of metal ions into her body. She filed a lawsuit in federal court in May 2013.
In January 2014, Biomet agreed to settle all M2a Magnum cases for a combined $56 million. That amounted to a base award of $200,000 for each plaintiff.
The Biomet hip settlement was available for cases in the federal MDL as well as state courts. To participate, injured consumers had to file their claims in state or federal court by April 15, 2014.
People who received a Biomet M2a 38 or M2a Magnum hip replacement system as part of an initial hip replacement that was revised more than 180 days after it was implanted were eligible for a base award of $200,000.
Biomet said it would only fund the settlement if 90 percent of the qualifying cases accepted the settlement. Plaintiffs had to submit information to the court by June 13, 2014. In its 2015 annual report, Zimmer Biomet estimated that it would take $33.4 million to resolve pending claims.
Please seek the advice of a medical professional before making health care decisions.
Chris Elkins is a writer and researcher for Drugwatch.com. He’s worked for various newspapers and has writing experience in sports, health communication and public relations fields. He graduated from the University of West Florida with a master’s degree in Strategic Communication and Leadership, a graduate-level certificate in Health Communication Leadership and a bachelor’s degree in Journalism.
Are you experiencing complications after undergoing a total hip replacement?